News
EXEL
21.02
-0.19%
-0.04
Buy Rating for Exelixis: Navigating Patent Lifecycles and Bolstering Growth with a Robust Pipeline
TipRanks · 1d ago
Exelixis reaches Cabometyx patent settlement with Cipla
Healthcare Exelixis reaches Cabometyx patent settlement with Cipla. ExelIXis has reached an agreement with India's cipla in regards to the latter's potential marketing of a generic version of cabometyx. The companies will also end all Hatch-Waxman litigation.
Seeking Alpha · 1d ago
EXELIXIS ANNOUNCES SETTLEMENT OF CABOMETYX® (CABOZANTINIB) PATENT LITIGATION WITH CIPLA LIMITED AND CIPLA USA
Reuters · 1d ago
EXELIXIS-PARTIES WILL TERMINATE ALL ONGOING HATCH-WAXMAN LITIGATION BETWEEN EXELIXIS, CIPLA REGARDING CABOMETYX PATENTS PENDING IN U.S. DISTRICT COURT
Reuters · 1d ago
Weekly Report: what happened at EXEL last week (0513-0517)?
Weekly Report · 1d ago
July 19th Options Now Available For Exelixis (EXEL)
NASDAQ · 4d ago
Oversold Conditions For Exelixis (EXEL)
NASDAQ · 05/14 15:51
Exelixis Price Target Announced at $23.00/Share by Stephens & Co.
Dow Jones · 05/14 13:44
Exelixis Initiated at Equal-Weight by Stephens & Co.
Dow Jones · 05/14 13:44
Stephens & Co. Initiates Coverage On Exelixis with Equal-Weight Rating, Announces Price Target of $23
Benzinga · 05/14 13:34
EXELIXIS INC <EXEL.O>: STEPHENS INITIATES COVERAGE WITH EQUAL-WEIGHT RATING; PRICE TARGET $23
Reuters · 05/14 10:29
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
Wall Street securities analysts revise their ratings and price targets on several companies. Akoya Biosciences, Boston Beer Company and Victory Capital Holdings are among the companies. Analysts raise target prices for Akoya, Boston beer company, Victory Capital and other companies. The analysts raised their ratings on Akoya and Boston Beer.
Reuters · 05/14 07:20
Weekly Report: what happened at EXEL last week (0506-0510)?
Weekly Report · 05/13 09:01
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Novo Nordisk and Exelixis are both experts in their respective fields. Novo Nordisk specializes in developing diabetes and obesity medicines. The company is also developing a cancer drug that could be a big hit. ExelIXis is a company that specializes in cancer medicines.
The Motley Fool · 05/12 17:25
Exelixis files patent suit against India’s Cipla over Cabometyx generics
Exelixis, Inc. Files patent suit against India’s Cipla over Cabometyx generics. The cancer drugmaker alleges that the Indian drugmaker has violated its patents related to the company's lead asset. Exelix is seeking to prevent the company from receiving FDA authorization for its generic version of cabometyx.
Seeking Alpha · 05/11 19:23
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment
Exelixis has filed a complaint for an alleged patent infringement against Cipla and its abbreviated new drug application. The company says it's seeking an order to make the effective date of any FDA approval after the expiration of its patents. The application is now pending with the Food and Drug Administration.
Dow Jones · 05/10 21:03
*Exelixis, Inc: Filed a Complaint in US District Court for the District of Delaware for Patent Infringement Against Cipla >EXEL
Dow Jones · 05/10 20:24
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
MacroGenics Inc released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine in prostate cancer. The company reported five deaths and over 50% rate of grade 3, or worse, adverse events. B Riley maintains the Buy rating on MacroGenics and BMO Capital Markets downgraded the company.
Benzinga · 05/10 19:08
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
Exelixis, Inc.'s (NASDAQ:EXEL) statutory profit was reduced by US$33m due to unusual items in the last 12 months. The company's earnings per share have grown at an impressive rate over the last three years. Exelix is has a strong profit, but investors should be optimistic about the company's future.
Simply Wall St · 05/07 11:25
Exelixis (EXEL) International Revenue Performance Explored
NASDAQ · 05/06 16:10
More
Webull provides a variety of real-time EXEL stock news. You can receive the latest news about Exelixis Inc through multiple platforms. This information may help you make smarter investment decisions.
About EXEL
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.